Histone demethylases in prostate cancer

Ling Yu Wang, Wenchang Guo, Kevin Kim, Mamata Pochampalli, Chiu Lien Hung, Yoshihiro Izumiya, Hsing Jien Kung

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Accumulating evidence has suggested that epigenetic alternations are as important as genetic mutations in cancer development. It is proposed that tumors are arisen by "malignant reprogramming" driven by a combination of both genetic and epigenetic changes. It therefore comes as no surprise that histone demethylases, the newest members of the histone modifying enzymes, are found to be targets of mutations and dysregulation in cancer cells. In this review article, we provide an overview of the types of histone demethylases whose genetic structure or expression is altered in cancers, the action of histone demethylases in cancer development and their potential inhibitors. Special emphasis is placed on the roles of histone demethylases in prostate cancer progression.

Original languageEnglish (US)
Title of host publicationNuclear Signaling Pathways and Targeting Transcription in Cancer
PublisherHumana Press Inc.
Pages373-397
Number of pages25
ISBN (Print)9781461480389
DOIs
StatePublished - 2014

Publication series

NameCancer Drug Discovery and Development
Volume88
ISSN (Print)2196-9906
ISSN (Electronic)2196-9914

Keywords

  • Epigenetics
  • Histone demethylase
  • Inhibitor
  • Mutation
  • Prostate cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Drug Discovery

Fingerprint Dive into the research topics of 'Histone demethylases in prostate cancer'. Together they form a unique fingerprint.

Cite this